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Aim: Unbalanced hemostasis and disseminated intravenous coagulopathy serve as key participants in organ dysfunction and disability.
In this study we evaluated the coagulation profiles of patients diagnosed with systemic inflammatory syndrome (SIRS)-sepsis and
multiple organ dysfunction syndrome. We also researched coagulation in sepsis by comparing thromboelastography (TEG) data with
those of nonsepsis patients to determine the usefulness of the TEG device.
Materials and methods: Data were collected from 55 anesthesiology and surgery intensive care unit (ICU) patients: 21 with SIRS-sepsis
(Group S) and 34 patients without SIRS-sepsis (Group C). Blood samples were taken upon admission to the ICU (t1) and on day 3 of
the ICU stay (t2). TEG data (R = reaction time, K = coagulation time, α = alpha angle, and MA = maximum amplitude) were recorded.
TEG parameters were compared with routine coagulation and hemogram studies.
Results: The mean R value in Group C was higher than that of Group S at both t1 and t2. Group S had a significantly lower K value and
higher alpha angle at t1 compared to Group C (P < 0.05).
Conclusion: Hypercoagulability was observed in SIRS-sepsis patients in the ICU, as measured with TEG. We believe that TEG will be a
useful tool in the evaluation of coagulation disorders developing in septic critically ill patients.
Key words: Sepsis, coagulation, thromboelastography

1. Introduction
Sepsis involves the invasion of blood and body tissues
by microorganisms and/or their toxins and the reactions
of the body against this invasion (1). During the 1992
American College of Chest Physicians/Society of Critical
Care Medicine Consensus Conference, sepsis was defined
as a systemic inflammatory response syndrome (SIRS)
caused by infection (2).
In sepsis, interactions among inflammation,
coagulation, and fibrinolysis, including disseminated
intravenous coagulopathy (DIC), create organ dysfunction;
these areas have also been the focus of new treatment
strategies in recent years (1,3). The initiating event in
sepsis is thought to be direct or indirect damage of the
endothelium by a microorganism or its toxin(s) (1–3).
Subendothelial tissues are then affected and collagenase is
released. In sepsis, activation of the extrinsic coagulation
cascade begins first, and then the intrinsic pathway increases
coagulation even more (1). The activation of both extrinsic
and intrinsic pathways results in increased availability of
thrombin. As a result, consumption coagulopathy (DIC)
may develop and spontaneous hemorrhages may occur.
* Correspondence: topcuismet@yahoo.com

However, severe hemorrhage diathesis is not common
(<3%) in critical patients (1).
Thromboelastography (TEG) uses full blood as its test
material and evaluates the whole coagulation system with
multiple parameters. TEG can determine the stability,
endurance, and kinetics of the coagulation system. Stability
and endurance reflect hemostasis and clot formation; its
kinetic parameters reveal whether factors are sufficient
enough in quantitative terms that clot formation will occur
(4,5).
In this study, TEG was examined for its usefulness in
the evaluation of coagulation disorders in patients with
sepsis.
2. Materials and methods
The study protocol was approved by the university’s board
of ethics. After obtaining informed consent, a suitable
group of patients admitted to the Anesthesiology and
Surgery Intensive Care Unit (ICU) between December
2009 and November 2010 were included in the study in a
prospective fashion.
The patients were assigned to 2 groups. Group S
(n = 21; sepsis) included the patients diagnosed with
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SIRS-sepsis and Group C (n = 34; control) included
patients admitted to the ICU without SIRS findings (2).
Exclusion criteria were age under 18 years, preexistent
hematological disorders, current oral anticoagulants, or
therapy to inhibit platelet aggregation. Demographic and
clinical characteristics of patients were recorded, including
vital signs, diagnoses, DIC, APACHE II score, length of
hospital stay, and use of mechanical ventilation, blood
or blood products, vasopressors, and anticoagulant and
antiplatelet agents. Diagnosis of DIC was proven when
prolongation in prothrombin time (PT) and activated
partial thromboplastin time (aPTT), low platelet and
fibrinogen levels, and an increase in D-dimer and other
fibrin split products were observed.
Blood samples were taken upon admission to the ICU
(baseline, t1) and at the end of the third day (t2). TEG
analysis was done by an anesthesiologist blinded to the
study group of the patient using a Thrombelastograph 5000
coagulation analyzer (Haemonetics Corp., Braintree, MA,
USA). The TEG device was adjusted to measure at 37 °C.
First, 1 mL was taken from the citrated blood sample and
mixed in a kaolin tube by gentle shaking. Next, 340 µL of
blood was taken from this blood sample with an automatic
pipette and put into the TEG tube, and then 20 µL of
calcium was added to the tube to eliminate the effect of
citrate. A disposable piston covered with plastic was placed
into the blood sample by a wire. The TEG tool was started
and the following standard TEG data were recorded:
reaction time (R, normally 3–8 min), coagulation time
(K, normally 1–3 min), alpha angle (α, normally 55–78°),
and maximum amplitude (MA, normally 51–69 mm).
Results from coagulated samples and systematic errors
were excluded from data analysis. In addition, routine

coagulation tests [PT, aPTT, and international normalized
ratio (INR)], hemoglobin, hematocrit, platelet (PLT)
count, white blood cell (WBC) count, and procalcitonin
(PCT) levels were measured on admission to the ICU and
on day 3.
2.1. Statistical analysis
Measured TEG parameters were compared with the
bleeding profile of patients in the sepsis and control
groups. Power analysis revealed that a minimum sample
size of 20 patients was required to achieve a power (β)
of 0.80, with a significance level of 95% (α = 0.05). All
statistical calculations were performed with SPSS 14.0
for Windows (SPSS Inc., Chicago, IL, USA). Means ±
standard deviations (SDs) were calculated for continuous
variables. Chi-square and Mann–Whitney U tests were
used to compare TEG and routine coagulation parameter
results. Findings were considered statistically significant if
the P-value was less than 0.05.
3. Results
During the study period, 21 patients with SIRS-sepsis
(Group S, mean age of 57 ± 18 years) and 34 control
patients without SIRS-sepsis (Group C, mean age of 58 ±
16 years) were included. The groups were not significantly
different in age, weight, or sex. APACHE II scores were
significantly higher in Group S patients (Table 1). Within
28 days of admission to the ICU, 9 (48%) patients in Group
S and 2 (5.88%) patients in Group C died.
While the majority (52%) of Group S patients were
postoperative patients, 19% were trauma patients, 14% were
infectious disease patients, 10% were postcardiopulmonary
resuscitation (post-CPR) patients, and 5% were suffering

Table 1. Demographic data of patients.
Group S
(n = 21)

Group C
(n = 34)

P-value

Age (years)

57.47 ± 17.63

58.17 ± 15.67

0.96

Sex (M/F)

10 / 11

15 / 19

0.804

Weight (kg)

86.61 ± 17.12

78.44 ± 18.0

0.13

APACHE II

23.61 ± 10.14

7.97 ± 3.22

0.0001

Diagnosis of patients
Postoperative patient
Trauma
Infectious disease
Post-CPR patient
Pulmonary disease
Intoxication

11 (52%)
4 (19%)
3 (14%)
2 (10%)
1 (5%)
-

22
5
3
2
2

0.252

Data are reported as mean ± SD. S: sepsis patients, C: control patients, M: male,
F: female, APACHE II: Acute Pathophysiology and Chronic Health Evaluation
II score.
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from pulmonary diseases. The majority (65%) of Group C
patients were also postoperative patients. The distribution
of diagnoses in the 2 groups was not significantly different
(P = 0.252).
Use of medications affecting the hemostatic system was
similar in the 2 groups, and DIC occurred in only 1 patient
from Group S (P = 0.199). Use of mechanical ventilation
and length of hospital stay were greater in Group S patients
(P = 0.003). Use of blood and blood products (P = 0.004),
vasopressors (P = 0.0001), and total parenteral nutrition (P
= 0.003) was also considerably higher in Group S (Table 2).
The first 28-day mortality rates were 47.6% (9 patients) and
5.88% (2 patients) in Group S and Group C, respectively (P
= 0.004).
When Group C and Group S were compared with
regard to basic SIRS criteria, significant differences were
found in all criteria (P < 0.05). At t1, significant differences
between the 2 groups were found in hemoglobin,
hematocrit, WBC, PLT, PT, aPTT, INR, and PCT values
(Table 3). At t2, hemoglobin, hematocrit, and aPTT values
were not significantly different (P > 0.05) (Table 3).
No significant differences were found between Group
S and Group C in diastolic blood pressure (DBP), mean
arterial pressure (MAP), or central venous pressure (CVP)
at t1 (P > 0.05) (Table 4). However, mean systolic blood
pressure (SBP) and PaO2/FiO2 rates in the 2 groups at t1
were significantly different (P < 0.05, Table 4).
The R value in Group S was lower than that of Group C
at t1 and t2 (P < 0.05), the K value was lower in Group S at
t1 (P < 0.05), and the alpha value was higher in Group S at
t1 (P < 0.05, Table 5).
4. Discussion
Early diagnosis of coagulation disorders, one of the
most important causes of mortality in sepsis, is a critical
aspect of sepsis treatment. In this study, we investigated
the efficacy of TEG as a diagnosis method in evaluating
the coagulation disorders of patients with sepsis. When

patients with sepsis were evaluated with TEG, we observed
hypercoagulability variations and saw that TEG is effective
in diagnosing coagulation disorders.
Sepsis affects many systems and causes hemodynamic
changes, which can progress to shock, organ dysfunction,
and organ failure (2). Despite advances in treatment, sepsis
maintains its importance because of its high morbidity
and mortality (6,7). Its incidence has increased in recent
years due to more widespread use of immunosuppressive
medications, more invasive therapies, and an overall
longer lifespan, which means more elderly patients who
have chronic diseases (6,8). Mortality rates resulting from
sepsis in various series have been reported to be between
20% and 60%, which are comparable to our results (48%
died within 28 days) (9–12).
Hematological dysfunction (as in DIC) occurring
within the first 24 h of sepsis treatment is associated with
a high rate of organ failure and death. In the early stages,
only prolongation of PT and aPTT may be seen. Eventually,
as a result of consumption of coagulation factors, sepsis
coagulopathy will occur (13). Early diagnosis is very
important so that treatment can be started promptly.
In our study, significant differences between Groups S
and C in PT, aPTT, and INR values were identified at t1;
however, by t2, differences remained only in PT and INR
values. In the multicenter Recombinant Human Activated
Protein C Worldwide Evaluation in Severe Sepsis study
(14), 93% of patients with sepsis had a prolonged PT and
63% of patients with sepsis had a prolonged aPTT. The
degree of coagulation test abnormalities correlated with
the intensity of the disease (15). DIC is characterized
by intravenous fibrin formation, which results in the
thrombotic obstruction of small- and medium-sized
vessels. In acute DIC, prolongation in PT and aPTT, low
platelet and fibrinogen levels, and an increase in D-dimer
and other fibrin split products are observed (16,17).
TEG analyzes the hemostatic system by evaluating
the viscoelastic and mechanical characteristics of the

Table 2. Clinical characteristics of patients within the first 3 days.

Length of hospital stay (days)
Use of blood products
Presence of DIC
Medications affecting the hemostatic system
Use of vasopressor
Mechanical ventilation support
Implementation of total parenteral nutrition

Group S
(n = 21)

Group C
(n = 34)

P-value

23 ± 14.16
18 (85.7)
1 (4.8)
10 (47.6)
10 (47.6)
16 (76.2)
11 (52.4)

62.11 ± 68.35
16 (47.1)
15 (44.1)
1 (2.9)
12 (35.3)
5 (14.7)

0.003
0.004
0.199
0.34
0.0001
0.003
0.003

Data are reported as n (%), S: sepsis patients, C: control patients, DIC: disseminated intravenous coagulopathy.
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Table 3. Laboratory data of patients.

Hemoglobin (g/dL)
Hematocrit (%)
WBC (cell/mm3)
PT (s)
aPTT (s)
PLT (×103)
INR
PCT (ng/mL)

Group S
(n = 21)

Group C
(n = 34)

P-value

t1

10.72 ± 1.6

12.01 ± 1.89

0.003

t2

10.8 ± 51.4

11.25 ± 1.96

0.621

t1

31.19 ± 4.52

35.64 ± 6.04

0.0001

t2

31.9 ± 4.27

33.06 ± 6.16

0.709

t1

16.76 ± 8.14

11.26 ± 3.49

0.004

t2

14.99 ± 7.83

11.63 ± 5.38

0.057

t1

17.35 ± 3.37

13.2 ± 2.22

0.0001

t2

15.25 ± 2.91

13.35 ± 1.94

0.006

t1

36.41 ± 6.39

27.5 ± 3.44

0.0001

t2

31.62 ± 10.47

28.62 ± 4.83

0.066

t1

135.14 ± 68.06

223.52 ± 94.96

0.0001

t2

155.04 ± 103.11

221.73 ± 77.64

0.009

t1

1.1 ± 0.28

1.06 ± 0.19

0.0001

t2

1.26 ± 0.82

1.06 ± 0.28

0.008

t1

30.51 ± 48.86

0.36 ± 0.46

0.001

t2

27.50 ± 53.23

0.23 ± 0.82

0.004

Data are reported as mean ± SD. S: sepsis patients, C: control patients, t1: day of
admission, t2: third day, WBC: white blood cell count, PT: prothrombin time,
aPTT: activated partial thromboplastin time, PLT: platelet count, INR: international
normalized ratio, PCT: procalcitonin.
Table 4. Hemodynamic and respiratory parameters of patients at t1.

SBP (mmHg)
DBP (mmHg)
MAP (mmHg)
CVP (mmHg)
PaO2/FiO2

Group S
(n = 21)

Group C
(n = 34)

P-value

104.8 ± 31.3
60.66 ± 14.82
76.47 ± 20.84
9.56 ± 5.75
193.62 ± 63.44

121.76 ± 17.64
66.47 ± 11.29
84.55 ± 11.29
8.57 ± 3.74
334.98 ± 106.10

0.01
0.083
0.074
0.920
0.0001

Data are reported as mean ± SD. t1: day of admission, S: sepsis patients, C: control
patients, SBP: systolic blood pressure, DBP: diastolic blood pressure, MAP: mean
arterial pressure, CVP: central venous pressure, PaO2/FiO2: partial pressure of
oxygen in arterial blood/fraction of inspired oxygen.

clot, a full dynamic process that differs from conventional
coagulation tests (18). TEG can identify a hypercoagulable
state quickly and is preferred in the postoperative
evaluation of coagulation (19). In our study, significant
differences in Groups S and C were found between the
TEG values (R, K, α angle, and MA) at t1 and t2, indicating
that TEG will better identify abnormal coagulation in the
septic patient.
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In a study of 28 patients with sepsis (DIC also in
12) and 10 control patients, TEG correctly identified
hypocoagulation in all who developed DIC and
hypercoagulation in all septic patients who did not
develop DIC (20). Accordingly, it was stated that TEG was
a suitable and efficient technique that easily demonstrated
the coagulation capacity of all patients with sepsis
(20). In a study of 30 patients with sepsis using rotation
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Table 5. Thromboelastography parameters of patients.

R (min)
K (min)
Alpha angle (°)
MA (mm)

Group S
(n = 21)

Group C
(n = 34)

P-value

t1

3.37 ± 1.65

5.05 ± 1.55

0.0001

t2

3.76 ± 1.91

5.12 ± 1.95

0.015

t1

1.6 ± 0.9

2.33 ± 1.42

0.041

t2

1.88 ± 1.73

2.10 ± 1.27

0.538

t1

72.97 ± 7.01

67.77 ± 8.88

0.027

t2

70.68 ± 8.71

68.34 ± 8.78

0.341

t1

67.11 ± 1.31

63.81 ± 9.996

0.262

t2

64.52 ± 14.84

63.41 ± 10.61

0.748

Data are reported as mean ± SD. t1: day of admission, t2: third day, S: sepsis patients,
C: control patients, R: reaction time, K: coagulation time; MA: maximum amplitude.

thromboelastography (ROTEM), a modified form of TEG,
ROTEM values changed significantly with the intensity
of sepsis and subsequent appearance (or not) of organ
dysfunction (21). The advantage of TEG is that it measures
the entire coagulation process from the beginning of fibrin
formation to clot lysis with minimal delays. In contrast,
routine coagulation tests measure the in vitro static state
of hemostasis and must be interpreted by correlating their
results with the clinical condition of the patients (22).
Spiel et al. (23) produced experimental endotoxemia by
giving lipid polysaccharide infusion to 16 volunteers and
evaluated ROTEM parameters. ROTEM demonstrated
not only changes related to coagulation but also changes
related to fibrinolysis (23). In a study by Collins et al.
(24), hemostasis disorder patients were evaluated with
both ROTEM and routine coagulation tests. Routine
coagulations tests were found to be inadequate to
predict thrombosis and multiorgan failure, but ROTEM
demonstrated the disorders of hemostasis more clearly
(24).
In a study of newborns with sepsis, TEG had 96%
sensitivity and 96% specificity in the diagnosis of
coagulation disorders; the authors stated that it should
be accepted as a simple, quick, and sensitive diagnostic
method (25). Reikvam et al. (26) showed the efficiency of
TEG in the diagnosis of coagulation disorders and stated

that the main advantage of TEG was in its ability to quickly
evaluate the hemostatic system of patients in a global
fashion.
Gonano et al. (27) investigated the coagulation profile of
septic patients before and during antithrombin treatment
(AT); they found pretreatment hypercoagulability in all
sepsis patients using TEG. Despite high antithrombin
plasma levels when receiving AT, the hypercoagulable
state did not normalize, as measured by both TEG and
standard coagulation tests (27). Just as we found, many
others have found TEG to be very sensitive in detecting
hypercoagulability (28–30).
Sepsis has a high mortality rate and should be
diagnosed early and treated without delay. Coagulation
disorders are among the most important causes of death
in sepsis, and thus early identification of a coagulation
disorder may be critical in prompting a clinician to initiate
treatment. Thromboelastography can rapidly give the
clinician an overview of the hemostatic condition of a
patient. We believe that TEG is very useful in the diagnosis
of coagulation disorders in sepsis.
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